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Abstract 
Background: Rett syndrome (RS) is a severe neurodevelopmental disorder for which there is no approved therapy. 
This study aimed to assess safety and efficacy of oral fingolimod in children with RS using a pre‑post and case–control 
design.
Methods: At the University of Basel Children’s Hospital, Basel, Switzerland, children with RS were included if they 
were older than 6 years and met the established diagnostic criteria of RS, including a positive MeCP2 mutation. Partici‑
pants were observed 6 months before and after treatment and received 12 months of fingolimod treatment. Serum 
samples of 50 children without RS served as reference for brain‑derived neurotrophic factor (BDNF) measurements. 
Primary outcome measures were safety and efficacy, the latter measured by change in levels of BDNF in serum/
CSF (cerebrospinal fluid) and change in deep gray matter volumes measured by magnetic resonance imaging (MRI). 
Secondary outcome measure was efficacy measured by change in clinical scores [Vineland Adaptive Behaviour Scale 
(VABS), Rett Severity Scale (RSSS) and Hand Apraxia Scale (HAS)].
Results: Six children with RS (all girls, mean and SD age 11.3 ± 3.1 years) were included. Serum samples of 50 children 
without RS (25 females, mean and SD age 13.5 ± 3.9 years) served as reference for BDNF measurements. No serious 
adverse events occurred. Primary and secondary outcome measures were not met. CSF BDNF levels were associated 
with all clinical scores: RSSS (estimate − 0.04, mult.effect 0.96, CI [0.94; 0.98], p = 0.03), HAS (estimate − 0.09, mult.effect 
0.91, CI [0.89; 0.94], p <  0.01) and VABS (communication: estimate 0.03, mult.effect 1.03, CI [1.02; 1.04], p < 0.01/daily 
living: estimate 0.03, mult.effect 1.03, CI [1.02; 1.04], p < 0.01/social skills: estimate 0.07, mult.effect 1.08, CI [1.05; 1.11], 
p < 0.01/motoric skills: estimate 0.04, mult.effect 1.04, CI [1.03; 1.06], p = 0.02).
Conclusions: In children with RS, treatment with fingolimod was safe. The study did not provide supportive evi‑
dence for an effect of fingolimod on clinical, laboratory, and imaging measures. CSF BDNF levels were associated with 
clinical scores, indicating a need to further evaluate its potential as a biomarker for RS. This finding should be further 
validated in independent patient groups.
Trial Registration: Clinical Trials.gov NCT02061137, registered on August 27th 2013, https ://clini caltr ials.gov/ct2/
show/study /NCT02 06113 7.
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Background
Rett syndrome (RS) is an X-linked neurodevelopmen-
tal disorder first described by Andreas Rett [1]. The 
classical variant is characterized by apparently normal 
development for the first 6–18  months, which shifts to 
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early-onset stagnation (stage 1), followed by a period 
of regression (stage 2) of motor and language skills, 
stereotypic hand movements (91%), epilepsy (64.2%), 
autonomic dysfunction (episodic hyperventilation and 
breath-holding, and cardiorespiratory symptoms in up to 
97%), and other symptoms, e.g., sleeping problems (80–
94%), walking difficulties (79%), dysphagia (61%), scolio-
sis (56%), which is then followed by a plateau phase (stage 
3) and a late motor deterioration phase (stage 4) [2–4]. 
The brains of patients with RS are smaller than those of 
healthy children but do not necessarily become progres-
sively smaller over time [5]. There is a global reduction 
in both gray and white matter volumes [6]. Indeed, neu-
roimaging studies revealed a global reduction in cortical 
brain volumes, a reduction in volume of the basal ganglia, 
and a reduced global blood flow as common features of 
RS [7] and immunohistochemical studies indicated pos-
sible white matter abnormalities [8]. In 1999, mutations 
in the MeCP2 gene encoding X-linked methyl-CpG-
binding protein 2 were identified as the cause of RS [9]. 
MeCP2 seems to be required to maintain neuronal func-
tion throughout life [10]. A key study that opened a win-
dow of opportunity for therapeutic interventions in RS 
showed a reversal of symptoms in a genetic mouse model 
after restoring MeCP2 [11].
Fingolimod is an oral drug that acts as a modulator of 
four of the five sphingosine-1 phosphate (S1P) receptors 
and is known to penetrate the blood–brain barrier [12]. 
Fingolimod was approved 10 years ago as a disease-mod-
ifying treatment for adults and, more recently, also for 
children with relapsing–remitting multiple sclerosis [13–
16]. In mice lacking MeCP2, fingolimod (FTY720) treat-
ment increased the levels of brain-derived neurotrophic 
factor (BDNF) and volume of deep and cortical gray 
matter and improved disease symptoms [17, 18]. BDNF 
is a member of the neurotrophin family; transcription is 
regulated by neural activity and its levels are known to be 
very low within the brain [19]. The significance of altered 
BDNF expression in RS has been demonstrated by pro-
viding evidence for a functional interaction between 
MeCP2 and BDNF [18].
This study aims to assess safety and efficacy of oral fin-
golimod in children with RS.
Methods
Participants
The study was performed at the Department of Pediat-
ric Neurology and Developmental Medicine at the Uni-
versity of Basel Children’s Hospital, Basel, Switzerland. 
The study was designed as an open-label phase I/II clini-
cal trial with a pre-post and case–control design. Par-
ticipants served as their own controls: Each participant 
was followed up for 6 months before treatment (M0-6), 
was thereafter treated for 12  months (M6-18), and was 
additionally followed up for another 6 months (M18-24). 
The study visit overview is shown in Additional file 1. For 
this first exploratory proof-of-concept study, we planned 
to recruit 6 patients with RS. Children were included in 
the study (treatment group) if they fulfilled the diagnos-
tic criteria for RS [20], were in stages II–IV [3, 21], had 
a confirmed MeCP2 mutation, were older than 6  years, 
and if parents had provided written informed consent. 
All study participants with RS were treated with fingoli-
mod. Age and weight limitations as well as dosing con-
siderations were based on pharmacokinetic modeling 
(performed by Novartis Pharma Schweiz AG): A dose 
of 0.5 mg was given for participants with a body weight 
over 40 kg, 0.25 mg for participants with a body weight 
of 15–40 kg.
To obtain reference values in a pediatric popula-
tion, serum BDNF levels were measured in blood sam-
ples from neurologically healthy children (HC), aged 
6–20 years, from whom blood had been drawn due to a 
routine surgical/gastrointestinal intervention.
Serum and CSF sampling and analysis
Serum and CSF samples for biomarkers were obtained at 
baseline (BL), first dose visit (FD, M6), after 6 months of 
treatment (M12), and at the end of the treatment period 
(M18). CSF sampling was performed under a short gen-
eral anesthesia with intravenous propofol.
Samples were analyzed using the Simoa BDNF Discov-
ery Kit and a Simoa HD-1-Analyzer. All serum samples 
were run twice, all CSF samples three times. The mean 
of all results was taken as the final result for each time 
point.
Analysis of CSF using liquid chromatography-mass 
spectrometry (LCMS): We prioritized the possible iden-
tification of BDNF by digesting recombinant BDNF with 
trypsin and analyzing the resulting peptides by LCMS 
using an Orbitrap Fusion Mass Spectrometer (Thermo 
Scientific, detailed methods available on request). To 
increase the possibility of identifying BDNF in  vivo, 
mass/charge (m/z), charge (z), and retention time (RT) 
values for peptides identified from the recombinant 
BDNF were then used to generate a priority inclusion list 
and the LCMS analysis was repeated using CSF samples 
as above, but the mass spectrometer was set to prioritize 
the fragmentation of peaks matching the inclusion list 
properties. Next, we analyzed CSF samples that had been 
spiked with increasing amounts of recombinant BDNF 
(ranging from 10 pg/ml to 18 ug/ml) using the inclusion 
list workflow described above to assess the threshold at 
which BDNF becomes detectable within CSF using our 
LCMS system.
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We also measured neurofilament light chain (NfL) as 
a specific marker of neuroaxonal damage [22–24] in all 
serum and CSF samples, as described previously [22], 
using the aliquots obtained for the BDNF analysis.
For reasons of safety, blood was sampled (liver 
enzymes, white blood cells/lymphocyte count) at M0 
(BL), M6 (FD), M7, M9, M12, M15, M18 (end of dose), 
and M24.
Levels of fingolimod (FTY-720 and FTY-720-P) in 
serum were measured before and six hours after admin-
istering the first dose, as well as one month after the first 
dose (M7) and after one year of treatment (M18) using 
mass spectrometry by WuXi AppTec (bioanalytical data 
report, property of Novartis Pharma Schweiz AG).
Clinical and imaging assessments
In addition to the standard clinical assessments, clini-
cal scores were assessed at M0, M6, M9, M12, M15, 
M18, M21, and M24 in patients and their families. These 
scores included the Vineland Adaptive Behaviour Scale 
(VABS) [25], the Rett Severity Scale (RSSS) [26], and the 
Hand Apraxia Scale (HAS) [27]. VABS addresses clini-
cal skills in communication (67 questions), daily living 
(92 questions), socialization (66 questions), and motor 
functions (36 questions). Possible answers are 0 (no/
never), 1 (sometimes), 2 (yes, regularly). Therefore, pos-
sible scores range from 0 to 522, a higher score reflecting 
a higher level of development. RSSS evaluates the clini-
cal manifestation of RS with regards to onset, growth, 
motor skills, communication skills, and other symptoms 
(respiration, autonomic function, onset of stereotypies, 
epilepsy, and seizures). Possible scores range from 1 to 
50, a higher score reflecting onset at earlier age and more 
impairment due to RS. HAS assesses 10 tasks (e.g., drink-
ing from a cup) and the total score reflects the sum of all 
items (every task counts for 1 point) that a child is una-
ble to do or does less than one-fourth of the time. Pos-
sible scores range from 0 to 10, a higher score reflecting a 
worse hand function.
Magnetic resonance imaging (MRI) was performed at 
M0, M6, M12, and M18 (with a short general anesthesia 
with intravenous propofol) on a 3.0  T magnetic reso-
nance scanner (Magnetom Skyra, Siemens Healthineers, 
Germany). Imaging included an axial, coronal, and sagit-
tal T1-weighted scout image to ensure correct head posi-
tioning followed by 3D T1w and 3D T2 SWI sequences. 
Deep gray matter volumes were segmented on the 3D 
T1w data (spatial resolution 1 × 1 × 1  mm3) measured 
using FSL-First (FSL version 5.0) as described previously 
[28, 29].
As an additional exploratory analysis, change in cer-
ebral blood flow (cortex and deep gray matter structures 
(Basal Ganglia, Thalamus, Hippocampus) was measured 
by using pulsed arterial spin labeling technique (pASL) 
combined with a 2D EPI read-out (slice thickness 5 mm 
with 1.25-mm gap, in-plane resolution 3.0 × 3.0  mm2 
interpolated to 1.5 × 1.5  mm2) [30, 31].
At M0, M6, and M18 a polysomnographic/electroen-
cephalographic investigation was performed and was 
quantified using a modified grand total of EEG score 
[32] (see Additional file 2). The grand total of EEG score 
reflects the visual assessment of an EEG, taking into 
account frequency and reactivity of background activity, 
paroxysmal activity, focal disturbances, and sharp wave 
activities. The total score ranges from 1 to 31, a higher 
score reflecting a more abnormal finding (total score of 1 
would be a normal EEG). The score was modified to meet 
the needs of children with RS: the major changes applied 
compared to the original score were the broader possible 
findings of paroxysmal activity and the replacement of 




1. Efficacy: change in levels of BDNF in serum/CSF 
(cerebrospinal fluid) and change in deep gray matter 
volumes (thalamus, caudate, putamen, pallidum, hip-
pocampus, amygdala and accumbens) measured by 
MRI.
2. Safety: white blood cell/lymphocyte counts, liver 
enzymes, and occurrence of any (serious) adverse 
events ((S)AE).
Secondary outcome measures:
1. Efficacy: Clinical scores (Vineland Adaptive Behav-
iour Scale, Rett Severity Scale and Hand Apraxia 
Scale), EEG patterns (grand total of EEG score), and 
breathing patterns.
Exploratory outcome measure:
1. Levels of NfL in serum/CSF as a biomarker for neu-
roaxonal loss.
2. Change in cerebral blood flow (cortex and deep 
gray matter structures (basal ganglia, thalamus, hip-
pocampus)) measured by MRI.
Statistical analysis
BDNF and NfL levels in serum were compared between 
patients with RS and healthy children (HC). Among the 
RS patients, we compared the average of the two meas-
urements at M0 and M6 (untreated time period). In one 
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patient there was no measurement at M6. In this case 
only the value at M0 was used. For BDNF p-values were 
estimated using a linear model, adjusted for thrombo-
cytes (Tc) and hematocrit (Hct) at the same visit, as pub-
lished previously [33]. BDNF was log-transformed prior 
to analysis. NfL was modeled in a robust model using the 
R-package robustbase (setting = “KS2014”). The p-values 
were adjusted for multiple comparisons using the Holm-
Bonferroni method.
Pearson’s correlation was calculated for BDNF serum 
and CSF levels after averaging all measurements of each 
patient.
Changes between M0 and M6 (before treatment) and 
M6 and M18 (with treatment) in BDNF and NfL, serum 
and cerebrospinal fluid (CSF) levels, and for clinical 
scores (VABS, RSSS, HAS) were assessed with paired 
t-tests. Only those RS patients were evaluated for whom 
data from measurements at M0, M6, and M18 were avail-
able (serum N = 5; CSF N = 4).
The association between BDNF and NfL in serum and 
CSF and the outcome scores at visits M0, M6, M12, and 
M18 were assessed in a simple linear model using gener-
alized estimating equations (GEE).
Brain volume changes between BL and M6 (before 
treatment) and M6 and M18 (treatment with fingolimod) 
were assessed. The average change between BL and M6 
as well as between M6 and M18 was estimated together 
with the 95% confidence interval and assessed in a paired 
t-test.
For the concurrent association between BDNF/NfL and 
regional brain volumes at BL, M6, M12, and M18 and 
between cortical and deep gray matter perfusion, brain 
volumes and perfusion served as dependent, BDNF/NfL 
as independent variables. The estimates were adjusted 
for patient age. The association was assessed in a linear 
model using GEE.
Ethical approval
The study was approved by the local ethics committee 
(EKNZ, Ref. 197/12) and by the Swiss agency for thera-
peutic products Swissmedic (Ref. 2013DR1109). Writ-
ten informed consent was obtained from all parents of 
participating children [RS (all) and HC (if children were 
younger than 14)] and from all healthy children (age 
6–10 oral informed consent only, but written informed 
consent from parents).
Results
Six children with RS (all female, mean and SD age 
11.3 ± 3.1  years) and 50 HC (25 females, mean and SD 
age 13.5 ± 3.9  years) were included and completed the 
study according to the protocol. Baseline characteristics 
of children with RS are shown in Table  1, those of HC 
in Additional file 3. No serious adverse events occurred. 
All participants were compliant with regards to the study 
medication even if oral intake was hindered by dysphagia 
(see Table 1).
At BL, serum BDNF levels in children with RS did not 
differ from those in HC [p = 0.708 (all HC, N = 50)/p = 1 
(only HC girls with age<15, N = 14)], nor did serum NfL 
levels at BL [p = 1 (all HC, N = 50)/p = 1 (only HC girls 
aged <15, N = 14)].
Serum BDNF levels at BL (ng/ml mean and SD) in 
patients with RS were 25.4 ± 7.2, in HC 22.14 (5.92). 
Serum NfL levels at BL (pg/ml mean and SD) in RS were 
10.0 ± 4.4, in HC 9.95 ± 5.56. CSF BDNF level at BL (pg/
ml mean and SD) in RS was 2.1 ± 2.7, CSF NfL level at 
BL (pg/ml mean and SD) in RS was 390.4 ± 303.1. There 
was no clear evidence of an age or gender effect regard-
ing BDNF and NfL in serum in 50 HC (Additional file 4). 
There was no evidence for a correlation between BDNF 
levels in serum and CSF (rho = 0.15, CI = [− 0.75; 0.86], 
p = 0.774).
There was no statistical evidence for a change in serum 
and CSF levels for BDNF and NfL over time (see Addi-
tional file 5). The average change within the clinical scales 
(VABS, RSSS, HAS) did not differ when compared before 
and during treatment (see Additional file 6).
No association was found between BDNF/NfL in 
serum and the clinical scores. CSF BDNF was associ-
ated with all clinical scores (Table  2): Increased RSSS 
and HAS (for both scales higher scores are less favora-
ble) were associated with lower BDNF in CSF, (RSSS: 
estimate − 0.04, mult.effect 0.96, CI [0.94; 0.98], p = 0.03/
HAS: estimate − 0.09, mult.effect 0.91, CI [0.89; 0.94], 
p<0.01) whereas higher VABS (higher scores are more 
favorable) are associated with higher BDNF (VABS com-
munication: estimate 0.03, mult.effect 1.03, CI [1.02; 
1.04], p<0.01/VABS daily living: estimate 0.03, mult.
effect 1.03, CI [1.02; 1.04], p<0.01/VABS social skills: esti-
mate 0.07, mult.effect 1.08, CI [1.05; 1.11], p<0.01/VABS 
motoric skills: estimate 0.04, mult.effect 1.04, CI [1.03; 
1.06], p = 0.02).
No association was found between NfL in CSF and 
the clinical scores (Table  2); nor were any consist-
ent changes found by assessing the average change in 
regional brain volumes before and during treatment (see 
Additional file  7). BDNF in serum was associated with 
the volumes of nucleus accumbens (estimate − 20.76, 
SE 4.89, CI [− 30.355; 11.171], p<0.01) and hippocam-
pus (estimate − 91.05, SE 43.22, CI [− 175.764;  − 6.333], 
p = 0.035). There was a strong association between 
increased NfL and a smaller deep gray matter volume 
(Table 3).
No association between BDNF (serum and CSF) and 
perfusion of cortex and hippocampus could be shown. 
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6 001 002 003 004 005 006
Number of females 
(%)
6 (100)
Age (mean and 
SD) in years
11.3 (3.1) 12 13 12 10 6 15
Disease duration 
(mean and SD) in 
years
10.4 (2.5) 10 12 10 9 5 12
Height (mean and 
SD) in cm
143.8 (12.8) 152 123.5 144.4 147 122 155
Weight (mean and 
SD) in kg
50.5 (24.8) 43.6 28.5 93.40 48 27 56
BMI (mean and SD) 23.9 (10.5) 19.0 15.7 44.7 22.2 18.1 23.3
Fingolimod dose 
(mg)











Normal Normal Opened capsule 
and given with 
liquid or meal
Opened capsule 




6 (100)  +  +  +  +  +  + 
Rett Stage (Hag‑
berg)
III III III IV III II
Seizures (%) 4 (66.7)  +  +  −  +  +  − 
AED 5 (83.3)  +  +  + (mood sta‑
bili − ser)
 +  +  − 
Hyper‑hypo‑venti‑
lation (%)
4 (66.7)  +  +  +  −  +  − 
Main symptoms 
at BL:
hand skills loss (%) 6 (100.0)  +  +  +  +  +  + 
spoken language 
loss (%)
6 (100.0)  +  +  +  +  +  + 
gait abnormalities 
(%)
6 (100.0)  +  +  +  +  +  + 
stereotypical 
moves (%)
5 (83.3)  +  + –  +  +  + 
Vineland Adaptive 
Behaviour Scale
41 44 89 47 45 160
Rett Symptom 
Severity Scale
18 25 6 18 28 4
Hand Apraxia Scale 7 10 9 10 10 3
MRI‑Inspection Normal Mode‑rate 
generalized 
atrophy
Micro‑cephaly Normal Decent general‑
ized atrophy
Normal
BDNF serum in ng/ml
16.79 26.59 23.95 20.77 38.16 25.90
Mean and SD 25.4 (7.2)
Median [IQR] 24.9 [21.6, 26.4]
BDNF csf in pg/ml
0.265 0.318 7.309 0.266 2.581 1.783
Mean and SD 2.1 (2.7)
Median [IQR] 1.1 [0.3, 2.4]
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We did observe an association between CSF BDNF (not 
for serum BDNF) and the perfusion of basal ganglia and 
thalamus (basal ganglia (estimate 0.94, SE 0.38, CI [0.199; 
1.673], p = 0.013)/thalamus (estimate 3.11, SE 1.14, CI 
[0.867; 5.351], p < 0.01). There was also an association 
between increased NfL (pg/ml in serum and CSF) and a 
lower perfusion in all areas measured (Table 4).
CSF BDNF levels could not be confirmed by liquid 
chromatography-mass spectrometry.
The average change in the grand total EEG scores did 
not differ when comparing the periods before and dur-
ing treatment. There was no change in breathing pattern 
abnormalities over the study period (polysomnography).
No SAEs occurred during the study period. There 
were 7 AE during the study period possibly related to 
the treatment (4/6 children, aphthosis (2), pharyngitis 
(1), viral gastroenteritis (1), and upper airway infec-
tions (3)). There was a slight increase in liver enzymes 
(see Additional file  8) and an expected decrease in 
Table 1 (continued)
All Individual patients
NfL serum in pg/ml
10.5 17.3 6.3 8.6 5.0 12.1
Mean and SD 10.0
(4.4)
Median [IQR] 9.6 [6.9, 11.7]
NfL CSF in pg/ml
305.3 1003.4 201.3 292.1 237.8 302.3
Mean and SD 390.4 (303.1)
Median [IQR] 297.2 [251.4, 304.6]
SD standard deviation, AED antiepileptic drug
Table 2 Association of  BDNF and  NfL in  CSF and  clinical 
scales
RSSS Rett Severity Scale, HAS Hand Apraxia Scale, VABS Vineland Adaptive 
Behaviour Scale
Clinical Score estimate Mult.effect CI p
BDNF
 RSSS  − 0.04 0.96 [0.94; 0.98] 0.03
 HAS  − 0.09 0.91 [0.89; 0.94] < 0.01
 VABS communication 
skills
0.03 1.03 [1.02; 1.04] < 0.01
 VABS daily living skills 0.03 1.03 [1.02; 1.04] < 0.01
 VABS social skills 0.07 1.08 [1.05; 1.11] < 0.01
 VABS motor skills 0.04 1.04 [1.03; 1.06] 0.02
NfL
 RSSS 0.02 1.03 [1.00; 1.05] 0.28
 HAS 0.03 1.03 [0.99; 1.08] 0.45
 VABS communication 
skills
0.00 1.00 [1.00; 1.01] 0.8
 VABS daily living skills  − 0.00 1.00 [0.98; 1.01] 0.75
 VABS social skills  − 0.01 0.99 [0.97; 1.01] 0.53
 VABS motor skills  − 0.01 0.99 [0.97; 1.00] 0.43
Table 3 Association between  BDNF/NfL and  deep gray 
matter volumes at the same visit, adjusted for age
Brain region Source Estimate SE CI p
BDNF
 Thalamus Serum − 145.97 117.07 [− 375.429; 83.493] 0.212
CSF 214.06 139.28 [− 58.925; 487.047] 0.124
 Caudate Serum − 53.78 43.26 [− 138.569; 30.999] 0.214
CSF 36.72 55.75 [− 72.561; 145.994] 0.510
 Putamen Serum − 51.60 82.04 [− 212.397; 109.191] 0.529
CSF 91.56 107.25 [− 118.650; 301.763] 0.393
 Pallidum Serum − 24.99 30.76 [− 85.287; 35.303] 0.417
CSF 59.34 39.40 [− 17.888; 136.572] 0.132
 Hippocam‑
pus
Serum − 91.05 43.22 [− 175.764;  − 6.333] 0.035
CSF − 13.73 64.68 [− 140.512; 113.046] 0.832
 Amygdala Serum − 16.06 23.46 [− 62.032; 29.920] 0.494
CSF 16.23 27.50 [− 37.673; 70.130] 0.555
 Accumbens Serum − 20.76 4.89 [− 30.355;  − 11.171] < 0.01
CSF 15.93 11.83 [− 7.255; 39.124] 0.178
NfL
 Thalamus Serum − 79.96 34.05 [− 146.704;  − 13.216] 0.019
CSF − 2.41 0.81 [− 3.994;  − 0.829]  < 0.01
 Caudate Serum − 37.81 12.57 [− 62.440;  − 13.185]  < 0.01
CSF − 1.14 0.30 [− 1.735;  − 0.554]  < 0.01
 Putamen Serum − 33.13 24.04 [− 80.253; 13.985] 0.168
CSF − 1.45 0.44 [− 2.318;  − 0.588] < 0.01
 Pallidum Serum − 24.58 8.60 [− 41.442;  − 7.717] < 0.01
CSF − 0.74 0.20 [− 1.127;  − 0.349] < 0.01
 Hippocam‑
pus
Serum − 56.13 14.14 [− 83.846;  − 28.409] < 0.01
CSF − 1.12 0.55 [− 2.195;  − 0.048] 0.041
 Amygdala Serum − 8.60 6.66 [− 21.652; 4.457] 0.197
CSF − 0.40 0.14 [− 0.682;  − 0.124] < 0.01
 Accumbens Serum − 6.88 2.51 [− 11.803;  − 1.948] < 0.01
CSF − 0.11 0.10 [− 0.300; 0.081] 0.261
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white blood cells and in lymphocyte counts during the 
treatment phase (see Additional file 9).
Levels of fingolimod during the study phase were 
within the expected range, known from other fingoli-
mod trials (confidential data from Novartis, not shown). 
For levels of FTY720/FTY720P, see Additional file 10.
Discussion
This study details an attempt to use knowledge from a 
genetically defined animal model of Rett Syndrome and 
to apply it to the human condition. Mice lacking MeCP2 
presented decreased levels of BDNF in brain areas critical 
for motor function, including the striatum and the cer-
ebellum, and fingolimod has been shown to restore these 
levels [17, 18]. In addition, fingolimod improved motor 
coordination of MeCP2 null animals and increased the 
volume of the striatum [17], a brain area known to be 
reduced in animals lacking BDNF [34, 35]. In our study, 
fingolimod was well tolerated and safe over a treatment 
period of 12 months. This is in accordance with results of 
a phase III study in pediatric MS where fingolimod was 
also well tolerated [15]. Compliance with study medica-
tion was supported by the clear drop in the lymphocyte 
count and the FTY720/FTY720P levels measured in 
serum.
Serum BDNF levels at baseline did not differ between 
children with RS and HC.
We did not observe any consistent effects of the 
12-month fingolimod treatment on serum or CSF BDNF 
levels or on deep gray matter volumes. Neither did we 
find any indication of a consistent effect on clinical, neu-
rophysiological, and patient-reported outcomes. Thus, 
we were not able to reproduce the effects observed in the 
experimental model in the human disease.
When assessing the association between the levels of 
BDNF and deep gray matter volumes at all visits (using 
GEE), BDNF in serum, but not in the CSF, was associ-
ated with the volumes of the nucleus accumbens and 
hippocampus. The reason for this correlation is unclear 
given that the bulk of serum BDNF originates from 
platelets and ultimately megakaryocytes [36]. Interest-
ingly, BDNF levels in CSF did correlate with all outcome 
scores, with better scores being associated with higher 
BDNF levels. These results suggest that, unlike the levels 
of BDNF in serum, those in CSF may represent a valuable 
biomarker for RS. However, this assumption is not only 
based on a very small patient population, but the levels of 
BDNF in CSF are also so low that the presence of BDNF 
could not be confirmed independently by LCMS.
RS is understood to be a neurodevelopmental, not a 
neurodegenerative disease [5]. This notion is supported 
by NfL levels in serum, a marker of ongoing or recent 
neuroaxonal damage [24]: NfL levels at BL did not dif-
fer between patients with RS and 50 HC and there was 
no relevant change in levels over time in the fingolimod-
treated cohort. However, a clear association was noted 
between increased NfL and reduced volumes of nearly 
all brain areas, which is in line with previous findings in 
another patient population [23]. In addition, there was a 
strong association between increased NfL concentrations 
in serum and CSF and a lower perfusion in all measured 
areas, an observation possibly linked to the decreased, 
lower brain volumes.
Table 4 Association between  BDNF/NfL and  cerebral 
blood flow at the same visit, adjusted for age
*Cortex: includes cortex of Insula, occipital, parietal, and temporal lobes. Frontal 
cortex evaluation was not possible due to susceptibility artefacts
Brain region Source Estimate SE CI p
BDNF
 Cortex* Serum 0.10 0.55 [− 0.984; 1.185] 0.856
CSF 1.42 0.94 [− 0.415; 3.261] 0.129
 Insula Serum 0.35 0.59 [− 0.800; 1.505] 0.549
CSF 1.19 1.00 [− 0.761; 3.145] 0.232
 Occipital Serum − 0.20 0.74 [− 1.652; 1.260] 0.792
CSF 2.27 1.44 [− 0.547; 5.091] 0.114
 Parietal Serum 0.06 0.49 [− 0.904; 1.033] 0.896
CSF 1.59 0.87 [− 0.119; 3.309] 0.068
 Temporal Serum − 0.25 0.55 [− 1.327; 0.823] 0.646
CSF 1.21 1.02 [− 0.791; 3.219] 0.235
 Basal ganglia Serum − 0.08 0.26 [− 0.589; 0.432] 0.763
CSF 0.94 0.38 [0.199; 1.673] 0.013
 Thalamus Serum 0.02 0.77 [− 1.487; 1.535] 0.975
CSF 3.11 1.14 [0.867; 5.351] < 0.01
 Hippo‑campus Serum − 0.02 0.47 [− 0.950; 0.912] 0.967
CSF 1.12 0.69 [− 0.224; 2.464] 0.102
NfL
 Cortex* Serum − 0.58 0.11 [− 0.796;  − 0.368] < 0.01
CSF − 0.01 0.01 [− 0.023;  − 0.002] 0.018
 Insula Serum − 0.40 0.11 [− 0.610;  − 0.196] < 0.01
CSF − 0.01 0.00 [− 0.017;  − 0.005] < 0.01
 Occipital Serum − 0.91 0.14 [− 1.185;  − 0.637] < 0.01
CSF − 0.02 0.01 [− 0.034; 0.000] 0.049
 Parietal Serum − 0.70 0.14 [− 0.970;  − 0.434] < 0.01
CSF − 0.10 0.01 [− 0.025;  − 0.003] 0.011
 Temporal Serum − 0.65 0.11 [− 0.861;  − 0.449] < 0.01
CSF − 0.01 0.01 [− 0.025;  − 0.004] < 0.01
 Basal ganglia Serum − 0.38 0.07 [− 0.519;  − 0.237] < 0.01
CSF − 0.01 0.00 [− 0.014;  − 0.003] < 0.01
 Thalamus Serum − 0.53 0.14 [− 0.810;  − 0.251] < 0.01
CSF − 0.01 0.01 [− 0.026;  − 0.002] 0.019
 Hippo‑campus Serum − 0.47 0.10 [− 0.661;  − 0.269] < 0.01
CSF − 0.02 0.00 [− 0.023;  − 0.008] < 0.01
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Our study has several limitations. First, the number 
of RS patients was very small and the study is prob-
ably underpowered with regards to group comparisons 
of BDNF measurements by ELISA [33]. Secondly, our 
study design was not placebo controlled. Thirdly, given 
the lack of data on the use of fingolimod in young chil-
dren, 6  years was set as the lower age limit for study 
inclusion. Lastly, while potentially important, the results 
related to measurements of BDNF levels in CSF must be 
interpreted with caution as they could not be indepen-
dently validated with another method. The antibody-
based technique used here has been pushed to the limit 
and, although the antibody used has been previously 
validated, the levels measured were below the detection 
threshold of LCMS.
Conclusions
Fingolimod treatment in this patient group was safe. This 
study failed to support an effect of fingolimod on BDNF 
levels (serum and CSF) and on clinical/imaging outcome 
measures, however. The low levels of BDNF detected by 
ELISA in CSF correlated with all clinical outcome scores, 
thus indicating a need to further evaluate the possible 
role of BDNF in the pathogenesis of RS and its utility as 
a potential, novel biomarker for RS. This finding needs 
to be confirmed in independent patient samples and also 
subjected to rigorous biochemical validation.
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